Loading...
XCSE
BAVA
Market cap1.76bUSD
Apr 03, Last price  
151.05DKK
1D
0.07%
1Q
-24.34%
Jan 2017
-39.34%
Name

Bavarian Nordic A/S

Chart & Performance

D1W1MN
No data to show
P/E
12.01
P/S
2.08
EPS
12.58
Div Yield, %
—
Shrs. gr., 5y
13.93%
Rev. gr., 5y
53.88%
Revenues
5.72b
-19.06%
247,596,000175,292,000332,103,000208,805,00074,783,000314,072,000523,601,0001,016,636,0001,212,501,0001,216,815,0001,020,561,0001,006,742,0001,370,151,000500,617,000662,488,0001,852,383,0001,897,875,0003,150,793,0007,062,340,0005,716,206,000
Net income
988m
-33.03%
-94,730,000-160,937,000-63,504,000-216,242,000-395,988,000-576,969,000-324,339,000-240,001,000-46,729,00025,940,00059,426,00030,600,000181,343,000-361,927,000-346,777,000277,521,000-464,775,000-347,382,0001,475,189,000987,977,000
CFO
1.95b
+74.22%
-58,210,000-194,493,000163,165,00022,411,000-484,139,000-239,862,000-375,236,00020,100,000147,084,000338,749,000105,323,000267,601,000216,065,000-288,529,000-275,910,000571,911,000-358,500,000220,053,0001,119,206,0001,949,832,000
Earnings
May 09, 2025

Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
URL
https://www.bavarian-nordic.com/
IPO date
Nov 02, 1998
Employees
1,354
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,716,206
-19.06%
7,062,340
124.14%
3,150,793
66.02%
Cost of revenue
4,776,436
5,636,078
3,221,578
Unusual Expense (Income)
NOPBT
939,770
1,426,262
(70,785)
NOPBT Margin
16.44%
20.20%
Operating Taxes
(16,620)
7,754
15,771
Tax Rate
0.54%
NOPAT
956,390
1,418,508
(86,556)
Net income
987,977
-33.03%
1,475,189
-524.66%
(347,382)
-25.26%
Dividends
Dividend yield
Proceeds from repurchase of equity
99,335
1,678,442
28,590
BB yield
-0.67%
-12.33%
-0.19%
Debt
Debt current
41,544
46,546
1,130,070
Long-term debt
199,829
227,010
699,583
Deferred revenue
1
2,324,657
Other long-term liabilities
113,589
1,097,588
2,891,077
Net debt
(1,933,655)
(1,605,110)
(1,020,599)
Cash flow
Cash from operating activities
1,949,832
1,119,206
220,053
CAPEX
(82,661)
(977,405)
(1,381,575)
Cash from investing activities
(1,870,863)
(945,564)
(877,405)
Cash from financing activities
55,775
735,832
635,820
FCF
1,104,349
971,534
(1,373,898)
Balance
Cash
2,175,028
1,867,481
2,845,166
Long term investments
11,185
5,086
Excess cash
1,889,218
1,525,549
2,692,712
Stockholders' equity
11,222,745
10,341,469
7,151,450
Invested Capital
9,761,182
10,050,068
11,415,789
ROIC
9.66%
13.22%
ROCE
8.07%
12.29%
EV
Common stock shares outstanding
78,324
76,711
70,419
Price
189.35
6.71%
177.45
-16.85%
213.40
-20.61%
Market cap
14,830,733
8.95%
13,612,289
-9.42%
15,027,415
-11.41%
EV
12,897,078
12,007,179
14,006,816
EBITDA
1,564,670
1,980,083
328,462
EV/EBITDA
8.24
6.06
42.64
Interest
77,872
105,519
119,689
Interest/NOPBT
8.29%
7.40%